ArticleSe pu = Chinese journal of chromatography2024
[Preparation of chiral metal organic framework modified silica monolithic capillary column and its application in enantioseparations of chiral drugs].
Article in Se pu = Chinese journal of chromatography, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Comparison of chiral separation performance of (2-hydroxyethyl-Se pu = Chinese journal of chromatography · 2026Article
- [Preparation of a chiral porous organic cage-bonded silica high performance liquid chromatography stationary phase and its application to the resolution of chiral compounds].Se pu = Chinese journal of chromatography · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metal organic frameworks (MOFs) are crystalline compounds composed of metal ions (or metal clusters) and organic ligands. Chiral MOFs have been successfully utilized as novel materials for the separation of chiral enantiomers by chromatography, demonstrating excellent chiral separation performance. In this study, a chiral MOF-modified silica monolithic capillary column was used for pressurized capillary electrochromatography. First, a chiral MOF (Co-glycyl-L-glutamic acid, Co-L-GG) was synthesized. This MOF was then used to prepare a chiral capillary monolithic column via a one-step in situ polymerization method. The optimal conditions for preparing the chiral capillary monolithic column were determined as follows: Co-L-GG amount, 5 mg; polyethylene glycol amount, 0.96 mg; tetramethoxysilane dosage, 3.6 mL; trimethoxymethylsilane dosage, 0.4 mL. Next, the effects of the separation conditions on the separation of chiral drugs were investigated. Under the conditions of an applied voltage of -20 kV and a mobile phase consisting of acetonitrile and 20 mmol/L disodium hydrogen phosphate (80∶20, v/v), six chiral drugs were separated within 3 min, with baseline separation achieved for amlodipine, fluvastatin, and tryptophan. Moreover, the prepared chiral capillary monolithic column exhibited good reproducibility and stability. Finally, molecular docking studies were conducted using AutoDock to explore the chiral recognition mechanism, and the results were analyzed using Discovery Studio. The results indicated that larger differences in binding free energy between Co-L-GG and the enantiomers of the chiral drugs were correlated with higher enantioselectivity factors. However, this correlation did not necessarily lead to an increase in resolution. Co-L-GG, which is enriched with primary amines, secondary amines, and carbonyl groups, demonstrated enantiomeric recognition capability. In conclusion, this study demonstrates that chiral MOFs can be effectively used as chiral functional monomers to prepare chiral monolithic capillary columns, highlighting their significant potential for the separation and analysis of chiral compounds. The comprehensive exploration of the synthesis, characterization, and applications of these MOFs will help provide valuable insights into the development of advanced separation technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.